FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.

FOR IMMEDIATE RELEASE
P07-85
May 10, 2007
Media Inquiries:
301-827-6242
Consumer Inquiries:
888-INFO-FDA

Company Misrepresented Prescription Pain Reliever to Health Care Professionals
The U.S. Food and Drug Administration’s (FDA) Office of Criminal Investigations (OCI) announced today that The Purdue Frederick Company, Inc. has agreed to pay more than $700 million to resolve criminal charges and civil liabilities in connection with several illegal schemes to promote, market and sell OxyContin, a powerful prescription pain reliever that the company produces.

An investigation by OCI uncovered an extensive, long-term conspiracy by The Purdue Frederick Company, Inc. to generate the maximum amount of revenues possible from the sale of OxyContin through various illegal schemes. To further this goal, Purdue trained its sales representatives to make false representations to health care providers about the difficulty of extracting oxycodone, the active ingredient, from the OxyContin tablet; trained its sales force to represent to health care providers that OxyContin did not cause euphoria and was less addictive than immediate-release opiates; and allowed health care providers to entertain the erroneous belief that OxyContin was less addictive than morphine. In addition, Purdue falsely labeled OxyContin as providing “fewer peaks and valleys than with immediate-release oxycodone,” and by representing that “…delayed absorption as provided by OxyContin Tablets is believed to reduce the abuse liability of the drug.”

“FDA will not tolerate practices that falsely promote drug products and place consumers at health risk,” said Margaret O.K. Glavin, Associate Commissioner for Regulatory Affairs. “We will continue to do all we can to protect the public against drug companies and their representatives who are not truthful and bilk consumers of precious health care dollars.”

To resolve the criminal charges, Purdue pled guilty to a felony count of misbranding a drug with intent to defraud and mislead. As part of the plea, Purdue will pay a $600 million settlement. That amount includes a criminal fine, restitution to government agencies, and over $276 million in forfeiture. In a separate civil settlement, Purdue will pay $100.6 million to the United States.

In addition, Purdue’s current and former executive employees, Michael Friedman, Howard Udell and Dr. Paul Goldenheim, pled guilty to a misdemeanor violation of misbranding OxyContin by illegally promoting the drug as being less addictive, less subject to abuse, and less likely to cause tolerance and withdrawal than other pain medications.

This case was prosecuted by the U. S. Attorney’s Office for the Western District of Virginia and investigated by FDA’s Office of Criminal Investigations; the Internal Revenue Service’s Criminal Investigations Division; the U.S. Department of Health and Human Services’ Office of Inspector General; and the State Police Departments of Virginia and West Virginia. This case serves as an excellent example of federal and state law enforcement cooperation.

FMS Global News

Tenderpoints

Advertisements

About FMS Global News

Folllowing Rick Usher's death in December 2008, at his request in September of that year, I had agreed, as his principal contributor and an experienced journalist, to run the FMS Global News service due to his heavy commitments to music and raising research funds through this avenue. Following his sad and sudden death I hope to continue his work as he would have wished.
This entry was posted in Analgesics, Back Pain, Britain, Chronic Myofacial Pain, Chronic Pain, Clinical Pain, Drugs, Europe, Feeds, Fibrohugs, Fibrohugs News, Fibromyalgia, Fibromyalgia Blogs, Fibromyalgia News, Fibromyalgia News Belgium, Fibromyalgia News Deutschland, Fibromyalgia News France, Fibromyalgia News Israel, Fibromyalgia News Italy, Fibromyalgia News Japan, Fibromyalgia News Jerusalem, Fibromyalgia News Korea, Fibromyalgia News Southeast Asia, Fibromyalgia Press Releases, Fibromyalia News Germany, FMS Global News, Health, Medical, Myofacial Pain Syndrome, Narcotics, News, News Australia, News Belgium, News Canada, News France, News India, News Ireland, News Israel, News Italy, News Japan, News Jerusalem, News Korea, News Montreal, News Norway, News Quebec, News Saskatchewan, News Scotland, News Spain, News Sweden, News Turkey, News UK, North Carolina, Ontario, Ottawa, Pain, Pain Management, Palliative Care, Philadelphia, RSS, Tenderpoints, Toronto, US, Virginia, Washington DC, World, World News. Bookmark the permalink.

One Response to FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.

  1. Pingback: PressPosts / User / jbflowerpower / Submitted

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s